Product Dossier

BONDRONAT

Product Dossier for BONDRONAT (ibandronate sodium, Atnahs Pharma). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.

Sponsor: Atnahs Pharma
Active ingredient: ibandronate sodium
Therapeutic area: Oncology
Same area: TALZENNA
Same area: ZARZIO

What it is

BONDRONAT is a registered Australian medicine containing ibandronic acid available as an injection and tablet formulation.

Regulatory history

BONDRONAT injection (6 mg/6 mL) was first registered on the ARTG on 13 April 2004. BONDRONAT tablet (50 mg film-coated) was first registered on the ARTG on 24 August 2006.